NCT04589949 - Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) | Biotech Hunter

Enrollment

420

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

March 1, 2022

Conditions

Covid19

Interventions

BIOLOGICAL

ConvP

"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"

BIOLOGICAL

FFP

Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products

Trial Locations (11)

3000 CA

Erasmus Medical Center, Rotterdam

Unknown

Meander Medisch Centrum, Amersfoort

Rijnstate Ziekenhuis, Arnhem

Amphia Ziekenhuis, Breda

Groene Hart Ziekenhuis, Gouda

University Medical Center Groningen (UMCG), Groningen

Spaarne Gasthuis, Haarlem

Medisch Centrum Leeuwarden, Leeuwarden

Leids Universitair Medisch Centrum, Leiden

Sint Antonius Ziekenhuis, Nieuwegein

Bernhoven Hospital, Uden